{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "d3084a4a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/user/Desktop/medical_bot/Eye_Disease_Chatbot/research'"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%pwd\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e9572026",
   "metadata": {},
   "source": [
    "For geting back to root directory to load pdfs\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "c000242e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/user/Desktop/medical_bot/Eye_Disease_Chatbot'"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import os\n",
    "os.chdir(\"../\")\n",
    "\n",
    "%pwd"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "901b587a",
   "metadata": {},
   "source": [
    "Load Pdfs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "387d824e",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import PyPDFLoader, DirectoryLoader\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "5a64c4a1",
   "metadata": {},
   "outputs": [],
   "source": [
    "#extracting text from pdf files\n",
    "def load_pdfs(data):\n",
    "    loader = DirectoryLoader(\n",
    "        data,\n",
    "        glob=\"*.pdf\",\n",
    "        loader_cls=PyPDFLoader\n",
    "    )\n",
    "    documents = loader.load()\n",
    "    return documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "22fac495",
   "metadata": {},
   "outputs": [],
   "source": [
    "extract_pdfs = load_pdfs(\"Data\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "d00e3f94",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:55:31+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:55:31+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/DME_KB_Document.pdf', 'total_pages': 4, 'page': 0, 'page_label': '1'}, page_content='Diabetic Macular Edema (DME) — Comprehensive KB Entry\\n1 — Short Definition\\nDiabetic Macular Edema (DME) is a vision■threatening retinal condition caused by fluid accumulation\\nwithin the macula due to breakdown of the blood–retinal barrier in diabetic retinopathy. It leads to\\nintraretinal cysts, retinal thickening, and sometimes subretinal fluid, all visible on OCT.\\n2 — Pathophysiology\\n- Chronic hyperglycemia damages retinal capillary endothelial cells and pericytes.\\n- Loss of pericytes → microaneurysms and capillary leakage.\\n- Increased VEGF and inflammatory cytokines promote vascular permeability.\\n- Breakdown of the inner blood–retinal barrier causes fluid entry into retinal layers.\\n- Fluid accumulates as intraretinal cystoid spaces, spongiform thickening, and occasionally subretinal\\nfluid.\\n- Chronic DME results in photoreceptor layer disruption and poor visual prognosis.\\n3 — Key OCT Imaging Features (Layer■Level)\\n- **Intraretinal cystoid spaces (IRF):** Hyporeflective, round pockets mainly in inner nuclear layer and\\nouter plexiform layer.\\n- **Diffuse retinal thickening:** “Spongiform” appearance with loss of normal retinal layer definition.\\n- **Subretinal fluid (SRF):** Hyporeflective space beneath the neurosensory retina in more severe\\ncases.\\n- **Hard exudates:** Hyperreflective foci, often located in outer plexiform layer.\\n- **Ellipsoid zone and ELM disruption:** Indicates photoreceptor injury → poorer prognosis.\\n- **Foveal contour changes:** Flattening or focal elevation depending on edema pattern.\\n- **Vitreomacular traction (VMT):** Occasionally contributes to persistent edema.\\n4 — Classification / Patterns of DME (OCT■Based)\\n- **Diffuse retinal thickening (DRT):** Spongiform swelling.\\n- **Cystoid macular edema (CME):** Presence of well■formed cysts.\\n- **Serous retinal detachment (SRD):** SRF without RPE detachment.\\n- **Mixed type:** Combination of the above.\\n- **Tractional / VMT■associated:** Structural traction contributes to edema persistence.\\n5 — Diagnosis\\nDiagnosis is based on:\\n- OCT showing intraretinal cysts, thickening, or SRF.\\n- Evidence of diabetic retinopathy on fundus examination.\\n- Symptoms: blurred central vision, fluctuating vision, difficulty reading.\\n6 — Treatment Overview (Detailed)'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:55:31+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:55:31+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/DME_KB_Document.pdf', 'total_pages': 4, 'page': 1, 'page_label': '2'}, page_content='DME treatment is individualized based on OCT findings, visual acuity, systemic factors, and\\npatient-specific considerations.\\n### A. First■Line: Anti■VEGF Intravitreal Injections\\nThese agents reduce vascular permeability and improve edema.\\n1. **Aflibercept (Eylea)**\\n- Dose: 2 mg (0.05 mL) intravitreal.\\n- Protocol: Monthly for 5 injections → then every 8 weeks or treat-and-extend.\\n- Particularly effective for patients with poor baseline vision.\\n2. **Ranibizumab (Lucentis)**\\n- Dose: 0.3 mg (US) or 0.5 mg (global) intravitreal.\\n- Protocol: Monthly until stable → then PRN or T&E.;\\n- Well-studied in DME with robust visual gains.\\n3. **Bevacizumab (Avastin)** (Off-label but widely used)\\n- Dose: 1.25 mg intravitreal.\\n- Cost-effective option; commonly used in resource-limited settings.\\n### B. Steroid Therapy (for chronic or anti■VEGF non■responders)\\nUseful for inflammatory components of DME.\\n1. **Dexamethasone intravitreal implant (Ozurdex)**\\n- Provides sustained release.\\n- Effective for ~3–4 months; repeat dosing needed.\\n2. **Fluocinolone acetonide implant (Iluvien)**\\n- Long-acting (up to 36 months).\\n- For chronic, recurrent DME insufficiently responsive to other treatments.\\n**Side effects of steroids:** IOP rise, cataract progression → monitor closely.\\n### C. Focal / Grid Laser Photocoagulation\\n- Historically first-line; now adjunctive.\\n- Used in non■center involving DME or when microaneurysms are focal sources of leakage.\\n- Helps stabilize edema rather than improve vision significantly.\\n### D. Surgical Approaches\\n- **Vitrectomy** indicated for tractional DME or significant VMT.\\n7 — Systemic Management (Important for Chatbot)\\nDME outcomes heavily depend on systemic control:'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:55:31+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:55:31+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/DME_KB_Document.pdf', 'total_pages': 4, 'page': 2, 'page_label': '3'}, page_content='- Tight blood glucose control (HbA1c optimization).\\n- Control blood pressure and lipids.\\n- Renal disease management.\\n- Lifestyle modifications (diet, exercise, smoking cessation).\\n8 — Patient Precautions & Advice\\n- Regular follow-up visits with OCT imaging are essential.\\n- Report sudden vision loss or new floaters immediately.\\n- Do not skip diabetes medications; coordinate with primary care.\\n- Understand that treatment often requires repeated injections; long-term therapy is common.\\n9 — Injection Procedure Precautions (Safety)\\n- Topical povidone-iodine is essential antisepsis.\\n- Sterile technique: gloves, mask, eyelid retraction.\\n- Avoid routine topical antibiotics before/after injection.\\n- Warn patients about endophthalmitis symptoms (pain, vision loss, redness).\\n- Mild irritation or foreign-body sensation is normal for 24 hours.\\n10 — Prognosis\\n- Anti■VEGF therapy improves or stabilizes vision in many patients.\\n- Poor prognostic markers include:\\n- Chronic edema\\n- Photoreceptor layer disruption\\n- Presence of large cysts or SRF\\n- Severe ischemia on angiography\\n- Early detection and consistent treatment improve outcomes.\\n11 — Decision Flow (For Chatbot Response Logic)\\n- OCT shows IRF/SRF with diabetic history → suggest active DME → needs retina specialist and\\nanti■VEGF therapy.\\n- No center involvement and mild leakage → may be observed or treated with focal laser.\\n- Anti■VEGF non-responder → consider steroids or evaluate for tractional components.\\n- If VMT present → surgical opinion needed.\\n12 — KB Snippets (Ready for Embedding)\\n- “DME is swelling in the central retina caused by diabetes-related leakage. It creates intraretinal cysts\\nvisible on OCT.”\\n- “Most cases require anti■VEGF injections; some chronic cases respond better to steroid implants.”\\n- “Tight blood sugar and blood pressure control greatly improve DME outcomes.”'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:55:31+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:55:31+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/DME_KB_Document.pdf', 'total_pages': 4, 'page': 3, 'page_label': '4'}, page_content='- “Report sudden vision loss immediately—may indicate worsening edema or hemorrhage.”\\n13 — Disclaimer\\nThis information is educational only and not a substitute for personalized medical advice. Treatment\\nplans vary; consult a retina specialist for individualized care.'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:56:23+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:56:23+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/NORMAL_KB_Document.pdf', 'total_pages': 3, 'page': 0, 'page_label': '1'}, page_content='Normal Retina — Comprehensive KB Entry\\n1 — Short Definition\\nA normal retina is a multilayered neural tissue lining the back of the eye, responsible for converting light\\ninto visual signals. On OCT imaging, the normal macula shows a clean foveal depression, well-defined\\nretinal layers, and absence of any fluid, cysts, or abnormal elevations.\\n2 — Basic Anatomy of the Retina (Layer by Layer)\\nFrom inner (vitreous side) to outer (RPE/choroid side), the key layers are:\\n- Internal Limiting Membrane (ILM)\\n- Nerve Fiber Layer (NFL)\\n- Ganglion Cell Layer (GCL)\\n- Inner Plexiform Layer (IPL)\\n- Inner Nuclear Layer (INL)\\n- Outer Plexiform Layer (OPL)\\n- Outer Nuclear Layer (ONL)\\n- External Limiting Membrane (ELM)\\n- Photoreceptor Inner Segments and Outer Segments\\n- Ellipsoid Zone (EZ)\\n- Retinal Pigment Epithelium (RPE)\\n- Bruch’s Membrane and Choroid beneath\\n3 — OCT Characteristics of a Healthy Macula\\n- **Foveal Depression:** Smooth, symmetric curvature with thinnest point at the fovea.\\n- **Layer Clarity:** All retinal layers appear sharply demarcated.\\n- **No Fluid:** No intraretinal cysts (IRF) and no subretinal fluid (SRF).\\n- **Intact Ellipsoid Zone:** Strong hyperreflective band indicating healthy photoreceptors.\\n- **Normal RPE Line:** Continuous, smooth hyperreflective line with no elevation.\\n- **Stable Thickness:** Normal macular thickness without thickening or thinning.\\n4 — What Is NOT Present in a Normal Retina (Important for Classification)\\n- No cystoid spaces.\\n- No drusen or sub-RPE deposits.\\n- No pigment epithelial detachment (PED).\\n- No choroidal neovascularization or subretinal hyperreflective material.\\n- No edema, exudates, or hemorrhage.\\n- No tractional changes or disruption of the photoreceptor bands.\\n5 — Physiological Variations (Still Considered Normal)'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:56:23+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:56:23+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/NORMAL_KB_Document.pdf', 'total_pages': 3, 'page': 1, 'page_label': '2'}, page_content='- Mild inter-individual variation in foveal pit shape.\\n- Slight differences in reflectivity due to age.\\n- Occasional benign vitreomacular adhesion (VMA) without traction.\\n6 — Importance in Machine Learning / Classification\\nA “normal” OCT class acts as:\\n- The baseline template for retinal architecture.\\n- The reference to detect abnormalities such as fluid, drusen, or neovascular membranes.\\n- A stabilizing anchor in the model for contrast between pathological and healthy states.\\n7 — Clinical Significance of Normal Findings\\n- Normal OCT suggests no active retinal disease.\\n- Clear layers and intact EZ correspond to good visual potential.\\n- Important for ruling out diabetic macular edema, drusen, and CNV.\\n8 — Patient Education (Chatbot-Friendly Snippets)\\n- “A normal retina has smooth, well-organized layers with no swelling or abnormal fluid.”\\n- “Your OCT scan shows no signs of leakage, deposits, or damage.”\\n- “An intact photoreceptor layer means healthy visual function.”\\n9 — When Normal OCT Occurs Despite Symptoms\\nA patient may feel symptoms but still have a normal OCT due to:\\n- Dry eye symptoms (not retinal).\\n- Migraine aura.\\n- Functional visual disturbances.\\n- Early disease not yet visible structurally.\\n10 — Safety & Advice for Patients with Normal OCT\\n- If vision symptoms persist, a clinical exam may still be needed.\\n- Monitor for any new distortion or vision changes.\\n- Maintain regular eye health practices (good lighting, glucose control if diabetic, etc.).\\n11 — Decision Flow (for Chatbot Use)\\n- OCT shows no fluid + intact layers → classify as NORMAL.\\n- If symptoms but OCT normal → recommend clinical evaluation for non-retinal causes.\\n- If minimal benign variations → still NORMAL unless accompanied by structural abnormalities.\\n12 — Snippets for Embedding\\n- “Normal OCT: clear layers, no fluid, intact RPE and photoreceptors.”\\n- “Healthy macula shows a smooth foveal dip with no cysts or swelling.”'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:56:23+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:56:23+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/NORMAL_KB_Document.pdf', 'total_pages': 3, 'page': 2, 'page_label': '3'}, page_content='- “No signs of drusen, edema, or abnormal vessels.”\\n13 — Disclaimer\\nThis information is for educational use only and should not replace clinical assessment by an eye care\\nprofessional.'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:51:09+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:51:09+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/CNV_KB_Document.pdf', 'total_pages': 2, 'page': 0, 'page_label': '1'}, page_content='Choroidal Neovascularization (CNV) — Comprehensive KB Entry\\n1 — Short definition\\nChoroidal neovascularization (CNV) is a process in which abnormal blood vessels grow from the\\nchoroid through breaks in Bruch’s membrane into sub-RPE and/or subretinal spaces, causing fluid\\nleakage, haemorrhage, and disruption of normal retinal architecture visible on OCT.\\n2 — Pathophysiology\\nNew vessels originate from the choroid and invade across Bruch’s membrane. Leakage from these\\nvessels produces subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hemorrhage; chronic\\nleakage causes scarring and photoreceptor loss.\\n3 — Imaging modalities\\nSpectral-domain OCT (SD-OCT) / Swept-source OCT — primary imaging for structural changes (fluid,\\nPEDs, SHRM).\\nOCT Angiography (OCTA) — visualizes CNV networks and detects flow within lesions.\\nFluorescein angiography (FA) — useful when OCT or OCTA are inconclusive.\\n4 — OCT appearances — layer-level description\\nSubretinal Hyperreflective Material (SHRM): hyperreflective dome/elevation above RPE; often contains\\nneovascular tissue.\\nPigment Epithelial Detachment (PED): elevation of RPE from Bruch’s membrane; often irregular in\\nCNV.\\nSubretinal Fluid (SRF): hyporeflective space between retina and RPE.\\nIntraretinal Fluid (IRF): cystoid hyporeflective pockets inside the retina.\\n5 — Diagnostic criteria\\nSymptoms + OCT structural evidence (SRF/IRF/SHRM/PED) + confirmation of neovascular flow on\\nOCTA or leakage on FA when needed.\\n6 — Staging / activity\\nActive CNV: presence of new or worsening SRF or IRF.\\nInactive CNV: absence of fluid, presence of stable scar tissue.\\n7 — First-line treatment — Anti-VEGF agents\\nRanibizumab: 0.5 mg intravitreal monthly or treat-and-extend.\\nAflibercept: 2 mg; loading phase monthly ×3 then every 8 weeks or T&E.;\\nBevacizumab: 1.25 mg intravitreal (off-label).'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:51:09+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:51:09+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/CNV_KB_Document.pdf', 'total_pages': 2, 'page': 1, 'page_label': '2'}, page_content='8 — Other therapies\\nPhotodynamic therapy (PDT) for select cases (less common today).\\n9 — Procedural precautions\\nUse povidone-iodine antisepsis, sterile technique, avoid routine antibiotics, counsel patient on warning\\nsigns of endophthalmitis.\\n10 — Complications\\nEndophthalmitis, inflammation, retinal detachment (rare), IOP spikes.\\n11 — Patient precautions\\nReport sudden vision worsening immediately. Maintain follow-ups. Control systemic vascular risks.\\nExpect mild discomfort post-injection.\\n12 — Prognosis\\nTimely anti-VEGF treatment stabilizes or improves vision in many cases; prognosis depends on\\nchronicity and photoreceptor layer integrity.\\n13 — Decision flow (for chatbot logic)\\nIf OCT shows active fluid → urgent retina care + anti-VEGF standard.\\nIf OCT shows no fluid → observe or extend treatment interval.\\n14 — Disclaimer\\nEducational information only; not a substitute for professional medical advice.'),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:52:26+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:52:26+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/DRUSEN_KB_Document.pdf', 'total_pages': 2, 'page': 0, 'page_label': '1'}, page_content=\"Drusen — Comprehensive KB Entry\\n1 — Short definition\\nDrusen are extracellular lipid-rich deposits that accumulate between the retinal pigment epithelium\\n(RPE) and Bruch's membrane. They are a hallmark sign of age-related macular degeneration (AMD)\\nspectrum but as an OCT feature they appear as RPE elevations with variable reflectivity.\\n2 — Pathophysiology\\nDrusen form from metabolic byproducts of the outer retina and RPE. Small hard drusen may be benign,\\nwhereas large soft or confluent drusen increase risk of progression to advanced disease (geographic\\natrophy or choroidal neovascularization).\\n3 — Imaging modalities\\nSpectral-domain OCT (SD-OCT) / Swept-source OCT — primary tool to visualize drusen morphology\\n(RPE elevations, hyperreflective foci).\\nColor fundus photography — shows yellowish deposits.\\nAutofluorescence imaging — useful to assess overlying RPE health.\\n4 — OCT appearances — layer-level description\\n- RPE Elevation: focal dome-like elevation of the RPE overlying hyporeflective/heterogeneous material.\\n- Drusen types: hard drusen (small, discrete), soft drusen (larger, confluent), cuticular drusen\\n(numerous, small).\\n- Hyperreflective foci: small reflective dots above drusen suggesting migration of RPE cells or\\ninflammatory cells.\\n- Overlying photoreceptor/ellipsoid zone integrity: disruption suggests higher risk of vision loss.\\n5 — Grading / staging (imaging-based)\\n- **Normal / No drusen**: no sub-RPE deposits.\\n- **Early**: few small drusen; minimal risk.\\n- **Intermediate**: medium/large drusen or pigmentary changes; increased risk of progression.\\n- **Advanced**: development of geographic atrophy or CNV (refer for treatment).\\n6 — Clinical significance\\n- Large/soft drusen and pigmentary changes correlate with higher risk of progression to advanced\\ndisease.\\n- Drusen themselves may be asymptomatic but serve as an important biomarker on OCT.\\n7 — Management & interventions\\n- **Observation and monitoring**: regular OCT and fundus exams depending on drusen size and risk.\\n- **Lifestyle interventions**: smoking cessation, healthy diet, control of cardiovascular risk factors.\\n- **AREDS2 supplementation**: evidence supports specific vitamin/mineral formulations for patients\\nwith intermediate AMD to slow progression (not useful for early/no drusen).\\n- **No routine invasive treatment for drusen alone**; treat complications (CNV) if they occur.\"),\n",
       " Document(metadata={'producer': 'ReportLab PDF Library - www.reportlab.com', 'creator': '(unspecified)', 'creationdate': '2025-12-10T12:52:26+00:00', 'author': '(anonymous)', 'keywords': '', 'moddate': '2025-12-10T12:52:26+00:00', 'subject': '(unspecified)', 'title': '(anonymous)', 'trapped': '/False', 'source': 'Data/DRUSEN_KB_Document.pdf', 'total_pages': 2, 'page': 1, 'page_label': '2'}, page_content='8 — Patient precautions & advice\\n- Encourage regular follow-ups with OCT imaging.\\n- Self-monitoring using an Amsler grid and reporting new distortion or central vision loss promptly.\\n- Avoid smoking; maintain healthy diet and control systemic risk factors.\\n9 — Prognosis\\n- Many patients with small drusen remain stable for years.\\n- Presence of large/confluent drusen and pigmentary changes increases risk of progression; timely\\nmonitoring and AREDS2 for eligible patients can reduce progression risk.\\n10 — Decision flow (for chatbot logic)\\n- If OCT shows only small isolated drusen and no symptoms → reassure + monitor.\\n- If OCT shows large/soft drusen or pigmentary changes → consider AREDS2 discussion and closer\\nfollow-up.\\n- If new fluid, hemorrhage, or signs of CNV appear → urgent retina referral.\\n11 — KB snippet suggestions (ready for embedding)\\n- Definition (patient): \"Drusen are small yellow deposits under the retina. They can be harmless but\\nsometimes signal increased risk for macular disease.\"\\n- Definition (clinician): \"Drusen are sub-RPE extracellular deposits; soft drusen and pigment changes\\nindicate higher progression risk.\"\\n- Management summary: \"Monitor with OCT; lifestyle changes; AREDS2 for intermediate disease; treat\\ncomplications if they arise.\"\\n12 — Citations & sources (suggested to fetch original PDFs)\\n- Review articles and OCT-focused papers on drusen morphology, AREDS2 trial summaries, and\\nimaging guides (search in PubMed Central / ophthalmology journals for drusen OCT morphology and\\nAREDS2 supplementation).\\n13 — Disclaimer\\nEducational information only; not a substitute for personalized medical advice. For decisions about\\nsupplements or treatment, consult a qualified eye care specialist.')]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extract_pdfs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "1529b352",
   "metadata": {},
   "outputs": [],
   "source": [
    "#filtering out empty documents\n",
    "from typing import List\n",
    "from langchain.schema import Document\n",
    "def filter_minimal(docs: List[Document])-> List[Document]:\n",
    "    \"\"\"\n",
    "    Given a list of Documents objects, retuern a new list of Document objects\n",
    "    containing only {source} and {page_content} attributes.\n",
    "    \"\"\"\n",
    "    filtered_docs : List[Document] = []\n",
    "    for doc in docs:\n",
    "        src = doc.metadata.get(\"source\")\n",
    "        filtered_docs.append(\n",
    "            Document(\n",
    "                page_content=doc.page_content,\n",
    "                metadata={\"source\": src}\n",
    "            )\n",
    "        )\n",
    "    return filtered_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "2674b071",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Diabetic Macular Edema (DME) — Comprehensive KB Entry\\n1 — Short Definition\\nDiabetic Macular Edema (DME) is a vision■threatening retinal condition caused by fluid accumulation\\nwithin the macula due to breakdown of the blood–retinal barrier in diabetic retinopathy. It leads to\\nintraretinal cysts, retinal thickening, and sometimes subretinal fluid, all visible on OCT.\\n2 — Pathophysiology\\n- Chronic hyperglycemia damages retinal capillary endothelial cells and pericytes.\\n- Loss of pericytes → microaneurysms and capillary leakage.\\n- Increased VEGF and inflammatory cytokines promote vascular permeability.\\n- Breakdown of the inner blood–retinal barrier causes fluid entry into retinal layers.\\n- Fluid accumulates as intraretinal cystoid spaces, spongiform thickening, and occasionally subretinal\\nfluid.\\n- Chronic DME results in photoreceptor layer disruption and poor visual prognosis.\\n3 — Key OCT Imaging Features (Layer■Level)\\n- **Intraretinal cystoid spaces (IRF):** Hyporeflective, round pockets mainly in inner nuclear layer and\\nouter plexiform layer.\\n- **Diffuse retinal thickening:** “Spongiform” appearance with loss of normal retinal layer definition.\\n- **Subretinal fluid (SRF):** Hyporeflective space beneath the neurosensory retina in more severe\\ncases.\\n- **Hard exudates:** Hyperreflective foci, often located in outer plexiform layer.\\n- **Ellipsoid zone and ELM disruption:** Indicates photoreceptor injury → poorer prognosis.\\n- **Foveal contour changes:** Flattening or focal elevation depending on edema pattern.\\n- **Vitreomacular traction (VMT):** Occasionally contributes to persistent edema.\\n4 — Classification / Patterns of DME (OCT■Based)\\n- **Diffuse retinal thickening (DRT):** Spongiform swelling.\\n- **Cystoid macular edema (CME):** Presence of well■formed cysts.\\n- **Serous retinal detachment (SRD):** SRF without RPE detachment.\\n- **Mixed type:** Combination of the above.\\n- **Tractional / VMT■associated:** Structural traction contributes to edema persistence.\\n5 — Diagnosis\\nDiagnosis is based on:\\n- OCT showing intraretinal cysts, thickening, or SRF.\\n- Evidence of diabetic retinopathy on fundus examination.\\n- Symptoms: blurred central vision, fluctuating vision, difficulty reading.\\n6 — Treatment Overview (Detailed)'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='DME treatment is individualized based on OCT findings, visual acuity, systemic factors, and\\npatient-specific considerations.\\n### A. First■Line: Anti■VEGF Intravitreal Injections\\nThese agents reduce vascular permeability and improve edema.\\n1. **Aflibercept (Eylea)**\\n- Dose: 2 mg (0.05 mL) intravitreal.\\n- Protocol: Monthly for 5 injections → then every 8 weeks or treat-and-extend.\\n- Particularly effective for patients with poor baseline vision.\\n2. **Ranibizumab (Lucentis)**\\n- Dose: 0.3 mg (US) or 0.5 mg (global) intravitreal.\\n- Protocol: Monthly until stable → then PRN or T&E.;\\n- Well-studied in DME with robust visual gains.\\n3. **Bevacizumab (Avastin)** (Off-label but widely used)\\n- Dose: 1.25 mg intravitreal.\\n- Cost-effective option; commonly used in resource-limited settings.\\n### B. Steroid Therapy (for chronic or anti■VEGF non■responders)\\nUseful for inflammatory components of DME.\\n1. **Dexamethasone intravitreal implant (Ozurdex)**\\n- Provides sustained release.\\n- Effective for ~3–4 months; repeat dosing needed.\\n2. **Fluocinolone acetonide implant (Iluvien)**\\n- Long-acting (up to 36 months).\\n- For chronic, recurrent DME insufficiently responsive to other treatments.\\n**Side effects of steroids:** IOP rise, cataract progression → monitor closely.\\n### C. Focal / Grid Laser Photocoagulation\\n- Historically first-line; now adjunctive.\\n- Used in non■center involving DME or when microaneurysms are focal sources of leakage.\\n- Helps stabilize edema rather than improve vision significantly.\\n### D. Surgical Approaches\\n- **Vitrectomy** indicated for tractional DME or significant VMT.\\n7 — Systemic Management (Important for Chatbot)\\nDME outcomes heavily depend on systemic control:'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Tight blood glucose control (HbA1c optimization).\\n- Control blood pressure and lipids.\\n- Renal disease management.\\n- Lifestyle modifications (diet, exercise, smoking cessation).\\n8 — Patient Precautions & Advice\\n- Regular follow-up visits with OCT imaging are essential.\\n- Report sudden vision loss or new floaters immediately.\\n- Do not skip diabetes medications; coordinate with primary care.\\n- Understand that treatment often requires repeated injections; long-term therapy is common.\\n9 — Injection Procedure Precautions (Safety)\\n- Topical povidone-iodine is essential antisepsis.\\n- Sterile technique: gloves, mask, eyelid retraction.\\n- Avoid routine topical antibiotics before/after injection.\\n- Warn patients about endophthalmitis symptoms (pain, vision loss, redness).\\n- Mild irritation or foreign-body sensation is normal for 24 hours.\\n10 — Prognosis\\n- Anti■VEGF therapy improves or stabilizes vision in many patients.\\n- Poor prognostic markers include:\\n- Chronic edema\\n- Photoreceptor layer disruption\\n- Presence of large cysts or SRF\\n- Severe ischemia on angiography\\n- Early detection and consistent treatment improve outcomes.\\n11 — Decision Flow (For Chatbot Response Logic)\\n- OCT shows IRF/SRF with diabetic history → suggest active DME → needs retina specialist and\\nanti■VEGF therapy.\\n- No center involvement and mild leakage → may be observed or treated with focal laser.\\n- Anti■VEGF non-responder → consider steroids or evaluate for tractional components.\\n- If VMT present → surgical opinion needed.\\n12 — KB Snippets (Ready for Embedding)\\n- “DME is swelling in the central retina caused by diabetes-related leakage. It creates intraretinal cysts\\nvisible on OCT.”\\n- “Most cases require anti■VEGF injections; some chronic cases respond better to steroid implants.”\\n- “Tight blood sugar and blood pressure control greatly improve DME outcomes.”'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- “Report sudden vision loss immediately—may indicate worsening edema or hemorrhage.”\\n13 — Disclaimer\\nThis information is educational only and not a substitute for personalized medical advice. Treatment\\nplans vary; consult a retina specialist for individualized care.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Normal Retina — Comprehensive KB Entry\\n1 — Short Definition\\nA normal retina is a multilayered neural tissue lining the back of the eye, responsible for converting light\\ninto visual signals. On OCT imaging, the normal macula shows a clean foveal depression, well-defined\\nretinal layers, and absence of any fluid, cysts, or abnormal elevations.\\n2 — Basic Anatomy of the Retina (Layer by Layer)\\nFrom inner (vitreous side) to outer (RPE/choroid side), the key layers are:\\n- Internal Limiting Membrane (ILM)\\n- Nerve Fiber Layer (NFL)\\n- Ganglion Cell Layer (GCL)\\n- Inner Plexiform Layer (IPL)\\n- Inner Nuclear Layer (INL)\\n- Outer Plexiform Layer (OPL)\\n- Outer Nuclear Layer (ONL)\\n- External Limiting Membrane (ELM)\\n- Photoreceptor Inner Segments and Outer Segments\\n- Ellipsoid Zone (EZ)\\n- Retinal Pigment Epithelium (RPE)\\n- Bruch’s Membrane and Choroid beneath\\n3 — OCT Characteristics of a Healthy Macula\\n- **Foveal Depression:** Smooth, symmetric curvature with thinnest point at the fovea.\\n- **Layer Clarity:** All retinal layers appear sharply demarcated.\\n- **No Fluid:** No intraretinal cysts (IRF) and no subretinal fluid (SRF).\\n- **Intact Ellipsoid Zone:** Strong hyperreflective band indicating healthy photoreceptors.\\n- **Normal RPE Line:** Continuous, smooth hyperreflective line with no elevation.\\n- **Stable Thickness:** Normal macular thickness without thickening or thinning.\\n4 — What Is NOT Present in a Normal Retina (Important for Classification)\\n- No cystoid spaces.\\n- No drusen or sub-RPE deposits.\\n- No pigment epithelial detachment (PED).\\n- No choroidal neovascularization or subretinal hyperreflective material.\\n- No edema, exudates, or hemorrhage.\\n- No tractional changes or disruption of the photoreceptor bands.\\n5 — Physiological Variations (Still Considered Normal)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Mild inter-individual variation in foveal pit shape.\\n- Slight differences in reflectivity due to age.\\n- Occasional benign vitreomacular adhesion (VMA) without traction.\\n6 — Importance in Machine Learning / Classification\\nA “normal” OCT class acts as:\\n- The baseline template for retinal architecture.\\n- The reference to detect abnormalities such as fluid, drusen, or neovascular membranes.\\n- A stabilizing anchor in the model for contrast between pathological and healthy states.\\n7 — Clinical Significance of Normal Findings\\n- Normal OCT suggests no active retinal disease.\\n- Clear layers and intact EZ correspond to good visual potential.\\n- Important for ruling out diabetic macular edema, drusen, and CNV.\\n8 — Patient Education (Chatbot-Friendly Snippets)\\n- “A normal retina has smooth, well-organized layers with no swelling or abnormal fluid.”\\n- “Your OCT scan shows no signs of leakage, deposits, or damage.”\\n- “An intact photoreceptor layer means healthy visual function.”\\n9 — When Normal OCT Occurs Despite Symptoms\\nA patient may feel symptoms but still have a normal OCT due to:\\n- Dry eye symptoms (not retinal).\\n- Migraine aura.\\n- Functional visual disturbances.\\n- Early disease not yet visible structurally.\\n10 — Safety & Advice for Patients with Normal OCT\\n- If vision symptoms persist, a clinical exam may still be needed.\\n- Monitor for any new distortion or vision changes.\\n- Maintain regular eye health practices (good lighting, glucose control if diabetic, etc.).\\n11 — Decision Flow (for Chatbot Use)\\n- OCT shows no fluid + intact layers → classify as NORMAL.\\n- If symptoms but OCT normal → recommend clinical evaluation for non-retinal causes.\\n- If minimal benign variations → still NORMAL unless accompanied by structural abnormalities.\\n12 — Snippets for Embedding\\n- “Normal OCT: clear layers, no fluid, intact RPE and photoreceptors.”\\n- “Healthy macula shows a smooth foveal dip with no cysts or swelling.”'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- “No signs of drusen, edema, or abnormal vessels.”\\n13 — Disclaimer\\nThis information is for educational use only and should not replace clinical assessment by an eye care\\nprofessional.'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Choroidal Neovascularization (CNV) — Comprehensive KB Entry\\n1 — Short definition\\nChoroidal neovascularization (CNV) is a process in which abnormal blood vessels grow from the\\nchoroid through breaks in Bruch’s membrane into sub-RPE and/or subretinal spaces, causing fluid\\nleakage, haemorrhage, and disruption of normal retinal architecture visible on OCT.\\n2 — Pathophysiology\\nNew vessels originate from the choroid and invade across Bruch’s membrane. Leakage from these\\nvessels produces subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hemorrhage; chronic\\nleakage causes scarring and photoreceptor loss.\\n3 — Imaging modalities\\nSpectral-domain OCT (SD-OCT) / Swept-source OCT — primary imaging for structural changes (fluid,\\nPEDs, SHRM).\\nOCT Angiography (OCTA) — visualizes CNV networks and detects flow within lesions.\\nFluorescein angiography (FA) — useful when OCT or OCTA are inconclusive.\\n4 — OCT appearances — layer-level description\\nSubretinal Hyperreflective Material (SHRM): hyperreflective dome/elevation above RPE; often contains\\nneovascular tissue.\\nPigment Epithelial Detachment (PED): elevation of RPE from Bruch’s membrane; often irregular in\\nCNV.\\nSubretinal Fluid (SRF): hyporeflective space between retina and RPE.\\nIntraretinal Fluid (IRF): cystoid hyporeflective pockets inside the retina.\\n5 — Diagnostic criteria\\nSymptoms + OCT structural evidence (SRF/IRF/SHRM/PED) + confirmation of neovascular flow on\\nOCTA or leakage on FA when needed.\\n6 — Staging / activity\\nActive CNV: presence of new or worsening SRF or IRF.\\nInactive CNV: absence of fluid, presence of stable scar tissue.\\n7 — First-line treatment — Anti-VEGF agents\\nRanibizumab: 0.5 mg intravitreal monthly or treat-and-extend.\\nAflibercept: 2 mg; loading phase monthly ×3 then every 8 weeks or T&E.;\\nBevacizumab: 1.25 mg intravitreal (off-label).'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='8 — Other therapies\\nPhotodynamic therapy (PDT) for select cases (less common today).\\n9 — Procedural precautions\\nUse povidone-iodine antisepsis, sterile technique, avoid routine antibiotics, counsel patient on warning\\nsigns of endophthalmitis.\\n10 — Complications\\nEndophthalmitis, inflammation, retinal detachment (rare), IOP spikes.\\n11 — Patient precautions\\nReport sudden vision worsening immediately. Maintain follow-ups. Control systemic vascular risks.\\nExpect mild discomfort post-injection.\\n12 — Prognosis\\nTimely anti-VEGF treatment stabilizes or improves vision in many cases; prognosis depends on\\nchronicity and photoreceptor layer integrity.\\n13 — Decision flow (for chatbot logic)\\nIf OCT shows active fluid → urgent retina care + anti-VEGF standard.\\nIf OCT shows no fluid → observe or extend treatment interval.\\n14 — Disclaimer\\nEducational information only; not a substitute for professional medical advice.'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content=\"Drusen — Comprehensive KB Entry\\n1 — Short definition\\nDrusen are extracellular lipid-rich deposits that accumulate between the retinal pigment epithelium\\n(RPE) and Bruch's membrane. They are a hallmark sign of age-related macular degeneration (AMD)\\nspectrum but as an OCT feature they appear as RPE elevations with variable reflectivity.\\n2 — Pathophysiology\\nDrusen form from metabolic byproducts of the outer retina and RPE. Small hard drusen may be benign,\\nwhereas large soft or confluent drusen increase risk of progression to advanced disease (geographic\\natrophy or choroidal neovascularization).\\n3 — Imaging modalities\\nSpectral-domain OCT (SD-OCT) / Swept-source OCT — primary tool to visualize drusen morphology\\n(RPE elevations, hyperreflective foci).\\nColor fundus photography — shows yellowish deposits.\\nAutofluorescence imaging — useful to assess overlying RPE health.\\n4 — OCT appearances — layer-level description\\n- RPE Elevation: focal dome-like elevation of the RPE overlying hyporeflective/heterogeneous material.\\n- Drusen types: hard drusen (small, discrete), soft drusen (larger, confluent), cuticular drusen\\n(numerous, small).\\n- Hyperreflective foci: small reflective dots above drusen suggesting migration of RPE cells or\\ninflammatory cells.\\n- Overlying photoreceptor/ellipsoid zone integrity: disruption suggests higher risk of vision loss.\\n5 — Grading / staging (imaging-based)\\n- **Normal / No drusen**: no sub-RPE deposits.\\n- **Early**: few small drusen; minimal risk.\\n- **Intermediate**: medium/large drusen or pigmentary changes; increased risk of progression.\\n- **Advanced**: development of geographic atrophy or CNV (refer for treatment).\\n6 — Clinical significance\\n- Large/soft drusen and pigmentary changes correlate with higher risk of progression to advanced\\ndisease.\\n- Drusen themselves may be asymptomatic but serve as an important biomarker on OCT.\\n7 — Management & interventions\\n- **Observation and monitoring**: regular OCT and fundus exams depending on drusen size and risk.\\n- **Lifestyle interventions**: smoking cessation, healthy diet, control of cardiovascular risk factors.\\n- **AREDS2 supplementation**: evidence supports specific vitamin/mineral formulations for patients\\nwith intermediate AMD to slow progression (not useful for early/no drusen).\\n- **No routine invasive treatment for drusen alone**; treat complications (CNV) if they occur.\"),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='8 — Patient precautions & advice\\n- Encourage regular follow-ups with OCT imaging.\\n- Self-monitoring using an Amsler grid and reporting new distortion or central vision loss promptly.\\n- Avoid smoking; maintain healthy diet and control systemic risk factors.\\n9 — Prognosis\\n- Many patients with small drusen remain stable for years.\\n- Presence of large/confluent drusen and pigmentary changes increases risk of progression; timely\\nmonitoring and AREDS2 for eligible patients can reduce progression risk.\\n10 — Decision flow (for chatbot logic)\\n- If OCT shows only small isolated drusen and no symptoms → reassure + monitor.\\n- If OCT shows large/soft drusen or pigmentary changes → consider AREDS2 discussion and closer\\nfollow-up.\\n- If new fluid, hemorrhage, or signs of CNV appear → urgent retina referral.\\n11 — KB snippet suggestions (ready for embedding)\\n- Definition (patient): \"Drusen are small yellow deposits under the retina. They can be harmless but\\nsometimes signal increased risk for macular disease.\"\\n- Definition (clinician): \"Drusen are sub-RPE extracellular deposits; soft drusen and pigment changes\\nindicate higher progression risk.\"\\n- Management summary: \"Monitor with OCT; lifestyle changes; AREDS2 for intermediate disease; treat\\ncomplications if they arise.\"\\n12 — Citations & sources (suggested to fetch original PDFs)\\n- Review articles and OCT-focused papers on drusen morphology, AREDS2 trial summaries, and\\nimaging guides (search in PubMed Central / ophthalmology journals for drusen OCT morphology and\\nAREDS2 supplementation).\\n13 — Disclaimer\\nEducational information only; not a substitute for personalized medical advice. For decisions about\\nsupplements or treatment, consult a qualified eye care specialist.')]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filtered_docs = filter_minimal(extract_pdfs)\n",
    "filtered_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "448fbe63",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "def clean_text(docs: List[Document]) -> List[Document]:\n",
    "    \"\"\"\n",
    "    Clean page_content for all documents in the list.\n",
    "    \"\"\"\n",
    "    cleaned_docs = []\n",
    "    for doc in docs:\n",
    "        # Remove non-ASCII characters and unwanted blocks\n",
    "        cleaned = re.sub(r'[^\\x00-\\x7F]+', '', doc.page_content)  # Remove non-ASCII\n",
    "        cleaned = re.sub(r'\\s+', ' ', cleaned).strip()  # Normalize whitespace\n",
    "        if cleaned:  # Skip empty after cleaning\n",
    "            cleaned_docs.append(Document(page_content=cleaned, metadata=doc.metadata))\n",
    "    return cleaned_docs\n",
    "\n",
    "# Apply to all filtered_docs\n",
    "cleaned_docs = clean_text(filtered_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "370a020e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Diabetic Macular Edema (DME) Comprehensive KB Entry 1 Short Definition Diabetic Macular Edema (DME) is a visionthreatening retinal condition caused by fluid accumulation within the macula due to breakdown of the bloodretinal barrier in diabetic retinopathy. It leads to intraretinal cysts, retinal thickening, and sometimes subretinal fluid, all visible on OCT. 2 Pathophysiology - Chronic hyperglycemia damages retinal capillary endothelial cells and pericytes. - Loss of pericytes microaneurysms and capillary leakage. - Increased VEGF and inflammatory cytokines promote vascular permeability. - Breakdown of the inner bloodretinal barrier causes fluid entry into retinal layers. - Fluid accumulates as intraretinal cystoid spaces, spongiform thickening, and occasionally subretinal fluid. - Chronic DME results in photoreceptor layer disruption and poor visual prognosis. 3 Key OCT Imaging Features (LayerLevel) - **Intraretinal cystoid spaces (IRF):** Hyporeflective, round pockets mainly in inner nuclear layer and outer plexiform layer. - **Diffuse retinal thickening:** Spongiform appearance with loss of normal retinal layer definition. - **Subretinal fluid (SRF):** Hyporeflective space beneath the neurosensory retina in more severe cases. - **Hard exudates:** Hyperreflective foci, often located in outer plexiform layer. - **Ellipsoid zone and ELM disruption:** Indicates photoreceptor injury poorer prognosis. - **Foveal contour changes:** Flattening or focal elevation depending on edema pattern. - **Vitreomacular traction (VMT):** Occasionally contributes to persistent edema. 4 Classification / Patterns of DME (OCTBased) - **Diffuse retinal thickening (DRT):** Spongiform swelling. - **Cystoid macular edema (CME):** Presence of wellformed cysts. - **Serous retinal detachment (SRD):** SRF without RPE detachment. - **Mixed type:** Combination of the above. - **Tractional / VMTassociated:** Structural traction contributes to edema persistence. 5 Diagnosis Diagnosis is based on: - OCT showing intraretinal cysts, thickening, or SRF. - Evidence of diabetic retinopathy on fundus examination. - Symptoms: blurred central vision, fluctuating vision, difficulty reading. 6 Treatment Overview (Detailed)'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='DME treatment is individualized based on OCT findings, visual acuity, systemic factors, and patient-specific considerations. ### A. FirstLine: AntiVEGF Intravitreal Injections These agents reduce vascular permeability and improve edema. 1. **Aflibercept (Eylea)** - Dose: 2 mg (0.05 mL) intravitreal. - Protocol: Monthly for 5 injections then every 8 weeks or treat-and-extend. - Particularly effective for patients with poor baseline vision. 2. **Ranibizumab (Lucentis)** - Dose: 0.3 mg (US) or 0.5 mg (global) intravitreal. - Protocol: Monthly until stable then PRN or T&E.; - Well-studied in DME with robust visual gains. 3. **Bevacizumab (Avastin)** (Off-label but widely used) - Dose: 1.25 mg intravitreal. - Cost-effective option; commonly used in resource-limited settings. ### B. Steroid Therapy (for chronic or antiVEGF nonresponders) Useful for inflammatory components of DME. 1. **Dexamethasone intravitreal implant (Ozurdex)** - Provides sustained release. - Effective for ~34 months; repeat dosing needed. 2. **Fluocinolone acetonide implant (Iluvien)** - Long-acting (up to 36 months). - For chronic, recurrent DME insufficiently responsive to other treatments. **Side effects of steroids:** IOP rise, cataract progression monitor closely. ### C. Focal / Grid Laser Photocoagulation - Historically first-line; now adjunctive. - Used in noncenter involving DME or when microaneurysms are focal sources of leakage. - Helps stabilize edema rather than improve vision significantly. ### D. Surgical Approaches - **Vitrectomy** indicated for tractional DME or significant VMT. 7 Systemic Management (Important for Chatbot) DME outcomes heavily depend on systemic control:'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Tight blood glucose control (HbA1c optimization). - Control blood pressure and lipids. - Renal disease management. - Lifestyle modifications (diet, exercise, smoking cessation). 8 Patient Precautions & Advice - Regular follow-up visits with OCT imaging are essential. - Report sudden vision loss or new floaters immediately. - Do not skip diabetes medications; coordinate with primary care. - Understand that treatment often requires repeated injections; long-term therapy is common. 9 Injection Procedure Precautions (Safety) - Topical povidone-iodine is essential antisepsis. - Sterile technique: gloves, mask, eyelid retraction. - Avoid routine topical antibiotics before/after injection. - Warn patients about endophthalmitis symptoms (pain, vision loss, redness). - Mild irritation or foreign-body sensation is normal for 24 hours. 10 Prognosis - AntiVEGF therapy improves or stabilizes vision in many patients. - Poor prognostic markers include: - Chronic edema - Photoreceptor layer disruption - Presence of large cysts or SRF - Severe ischemia on angiography - Early detection and consistent treatment improve outcomes. 11 Decision Flow (For Chatbot Response Logic) - OCT shows IRF/SRF with diabetic history suggest active DME needs retina specialist and antiVEGF therapy. - No center involvement and mild leakage may be observed or treated with focal laser. - AntiVEGF non-responder consider steroids or evaluate for tractional components. - If VMT present surgical opinion needed. 12 KB Snippets (Ready for Embedding) - DME is swelling in the central retina caused by diabetes-related leakage. It creates intraretinal cysts visible on OCT. - Most cases require antiVEGF injections; some chronic cases respond better to steroid implants. - Tight blood sugar and blood pressure control greatly improve DME outcomes.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Report sudden vision loss immediatelymay indicate worsening edema or hemorrhage. 13 Disclaimer This information is educational only and not a substitute for personalized medical advice. Treatment plans vary; consult a retina specialist for individualized care.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Normal Retina Comprehensive KB Entry 1 Short Definition A normal retina is a multilayered neural tissue lining the back of the eye, responsible for converting light into visual signals. On OCT imaging, the normal macula shows a clean foveal depression, well-defined retinal layers, and absence of any fluid, cysts, or abnormal elevations. 2 Basic Anatomy of the Retina (Layer by Layer) From inner (vitreous side) to outer (RPE/choroid side), the key layers are: - Internal Limiting Membrane (ILM) - Nerve Fiber Layer (NFL) - Ganglion Cell Layer (GCL) - Inner Plexiform Layer (IPL) - Inner Nuclear Layer (INL) - Outer Plexiform Layer (OPL) - Outer Nuclear Layer (ONL) - External Limiting Membrane (ELM) - Photoreceptor Inner Segments and Outer Segments - Ellipsoid Zone (EZ) - Retinal Pigment Epithelium (RPE) - Bruchs Membrane and Choroid beneath 3 OCT Characteristics of a Healthy Macula - **Foveal Depression:** Smooth, symmetric curvature with thinnest point at the fovea. - **Layer Clarity:** All retinal layers appear sharply demarcated. - **No Fluid:** No intraretinal cysts (IRF) and no subretinal fluid (SRF). - **Intact Ellipsoid Zone:** Strong hyperreflective band indicating healthy photoreceptors. - **Normal RPE Line:** Continuous, smooth hyperreflective line with no elevation. - **Stable Thickness:** Normal macular thickness without thickening or thinning. 4 What Is NOT Present in a Normal Retina (Important for Classification) - No cystoid spaces. - No drusen or sub-RPE deposits. - No pigment epithelial detachment (PED). - No choroidal neovascularization or subretinal hyperreflective material. - No edema, exudates, or hemorrhage. - No tractional changes or disruption of the photoreceptor bands. 5 Physiological Variations (Still Considered Normal)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Mild inter-individual variation in foveal pit shape. - Slight differences in reflectivity due to age. - Occasional benign vitreomacular adhesion (VMA) without traction. 6 Importance in Machine Learning / Classification A normal OCT class acts as: - The baseline template for retinal architecture. - The reference to detect abnormalities such as fluid, drusen, or neovascular membranes. - A stabilizing anchor in the model for contrast between pathological and healthy states. 7 Clinical Significance of Normal Findings - Normal OCT suggests no active retinal disease. - Clear layers and intact EZ correspond to good visual potential. - Important for ruling out diabetic macular edema, drusen, and CNV. 8 Patient Education (Chatbot-Friendly Snippets) - A normal retina has smooth, well-organized layers with no swelling or abnormal fluid. - Your OCT scan shows no signs of leakage, deposits, or damage. - An intact photoreceptor layer means healthy visual function. 9 When Normal OCT Occurs Despite Symptoms A patient may feel symptoms but still have a normal OCT due to: - Dry eye symptoms (not retinal). - Migraine aura. - Functional visual disturbances. - Early disease not yet visible structurally. 10 Safety & Advice for Patients with Normal OCT - If vision symptoms persist, a clinical exam may still be needed. - Monitor for any new distortion or vision changes. - Maintain regular eye health practices (good lighting, glucose control if diabetic, etc.). 11 Decision Flow (for Chatbot Use) - OCT shows no fluid + intact layers classify as NORMAL. - If symptoms but OCT normal recommend clinical evaluation for non-retinal causes. - If minimal benign variations still NORMAL unless accompanied by structural abnormalities. 12 Snippets for Embedding - Normal OCT: clear layers, no fluid, intact RPE and photoreceptors. - Healthy macula shows a smooth foveal dip with no cysts or swelling.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- No signs of drusen, edema, or abnormal vessels. 13 Disclaimer This information is for educational use only and should not replace clinical assessment by an eye care professional.'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Choroidal Neovascularization (CNV) Comprehensive KB Entry 1 Short definition Choroidal neovascularization (CNV) is a process in which abnormal blood vessels grow from the choroid through breaks in Bruchs membrane into sub-RPE and/or subretinal spaces, causing fluid leakage, haemorrhage, and disruption of normal retinal architecture visible on OCT. 2 Pathophysiology New vessels originate from the choroid and invade across Bruchs membrane. Leakage from these vessels produces subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hemorrhage; chronic leakage causes scarring and photoreceptor loss. 3 Imaging modalities Spectral-domain OCT (SD-OCT) / Swept-source OCT primary imaging for structural changes (fluid, PEDs, SHRM). OCT Angiography (OCTA) visualizes CNV networks and detects flow within lesions. Fluorescein angiography (FA) useful when OCT or OCTA are inconclusive. 4 OCT appearances layer-level description Subretinal Hyperreflective Material (SHRM): hyperreflective dome/elevation above RPE; often contains neovascular tissue. Pigment Epithelial Detachment (PED): elevation of RPE from Bruchs membrane; often irregular in CNV. Subretinal Fluid (SRF): hyporeflective space between retina and RPE. Intraretinal Fluid (IRF): cystoid hyporeflective pockets inside the retina. 5 Diagnostic criteria Symptoms + OCT structural evidence (SRF/IRF/SHRM/PED) + confirmation of neovascular flow on OCTA or leakage on FA when needed. 6 Staging / activity Active CNV: presence of new or worsening SRF or IRF. Inactive CNV: absence of fluid, presence of stable scar tissue. 7 First-line treatment Anti-VEGF agents Ranibizumab: 0.5 mg intravitreal monthly or treat-and-extend. Aflibercept: 2 mg; loading phase monthly 3 then every 8 weeks or T&E.; Bevacizumab: 1.25 mg intravitreal (off-label).'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='8 Other therapies Photodynamic therapy (PDT) for select cases (less common today). 9 Procedural precautions Use povidone-iodine antisepsis, sterile technique, avoid routine antibiotics, counsel patient on warning signs of endophthalmitis. 10 Complications Endophthalmitis, inflammation, retinal detachment (rare), IOP spikes. 11 Patient precautions Report sudden vision worsening immediately. Maintain follow-ups. Control systemic vascular risks. Expect mild discomfort post-injection. 12 Prognosis Timely anti-VEGF treatment stabilizes or improves vision in many cases; prognosis depends on chronicity and photoreceptor layer integrity. 13 Decision flow (for chatbot logic) If OCT shows active fluid urgent retina care + anti-VEGF standard. If OCT shows no fluid observe or extend treatment interval. 14 Disclaimer Educational information only; not a substitute for professional medical advice.'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content=\"Drusen Comprehensive KB Entry 1 Short definition Drusen are extracellular lipid-rich deposits that accumulate between the retinal pigment epithelium (RPE) and Bruch's membrane. They are a hallmark sign of age-related macular degeneration (AMD) spectrum but as an OCT feature they appear as RPE elevations with variable reflectivity. 2 Pathophysiology Drusen form from metabolic byproducts of the outer retina and RPE. Small hard drusen may be benign, whereas large soft or confluent drusen increase risk of progression to advanced disease (geographic atrophy or choroidal neovascularization). 3 Imaging modalities Spectral-domain OCT (SD-OCT) / Swept-source OCT primary tool to visualize drusen morphology (RPE elevations, hyperreflective foci). Color fundus photography shows yellowish deposits. Autofluorescence imaging useful to assess overlying RPE health. 4 OCT appearances layer-level description - RPE Elevation: focal dome-like elevation of the RPE overlying hyporeflective/heterogeneous material. - Drusen types: hard drusen (small, discrete), soft drusen (larger, confluent), cuticular drusen (numerous, small). - Hyperreflective foci: small reflective dots above drusen suggesting migration of RPE cells or inflammatory cells. - Overlying photoreceptor/ellipsoid zone integrity: disruption suggests higher risk of vision loss. 5 Grading / staging (imaging-based) - **Normal / No drusen**: no sub-RPE deposits. - **Early**: few small drusen; minimal risk. - **Intermediate**: medium/large drusen or pigmentary changes; increased risk of progression. - **Advanced**: development of geographic atrophy or CNV (refer for treatment). 6 Clinical significance - Large/soft drusen and pigmentary changes correlate with higher risk of progression to advanced disease. - Drusen themselves may be asymptomatic but serve as an important biomarker on OCT. 7 Management & interventions - **Observation and monitoring**: regular OCT and fundus exams depending on drusen size and risk. - **Lifestyle interventions**: smoking cessation, healthy diet, control of cardiovascular risk factors. - **AREDS2 supplementation**: evidence supports specific vitamin/mineral formulations for patients with intermediate AMD to slow progression (not useful for early/no drusen). - **No routine invasive treatment for drusen alone**; treat complications (CNV) if they occur.\"),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='8 Patient precautions & advice - Encourage regular follow-ups with OCT imaging. - Self-monitoring using an Amsler grid and reporting new distortion or central vision loss promptly. - Avoid smoking; maintain healthy diet and control systemic risk factors. 9 Prognosis - Many patients with small drusen remain stable for years. - Presence of large/confluent drusen and pigmentary changes increases risk of progression; timely monitoring and AREDS2 for eligible patients can reduce progression risk. 10 Decision flow (for chatbot logic) - If OCT shows only small isolated drusen and no symptoms reassure + monitor. - If OCT shows large/soft drusen or pigmentary changes consider AREDS2 discussion and closer follow-up. - If new fluid, hemorrhage, or signs of CNV appear urgent retina referral. 11 KB snippet suggestions (ready for embedding) - Definition (patient): \"Drusen are small yellow deposits under the retina. They can be harmless but sometimes signal increased risk for macular disease.\" - Definition (clinician): \"Drusen are sub-RPE extracellular deposits; soft drusen and pigment changes indicate higher progression risk.\" - Management summary: \"Monitor with OCT; lifestyle changes; AREDS2 for intermediate disease; treat complications if they arise.\" 12 Citations & sources (suggested to fetch original PDFs) - Review articles and OCT-focused papers on drusen morphology, AREDS2 trial summaries, and imaging guides (search in PubMed Central / ophthalmology journals for drusen OCT morphology and AREDS2 supplementation). 13 Disclaimer Educational information only; not a substitute for personalized medical advice. For decisions about supplements or treatment, consult a qualified eye care specialist.')]"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cleaned_docs"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "913f8080",
   "metadata": {},
   "source": [
    "Chucking\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "4d2ed2c1",
   "metadata": {},
   "outputs": [],
   "source": [
    "#splitting documents into smaller chunks\n",
    "def text_split(cleaned_docs):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "        chunk_size=45,\n",
    "        chunk_overlap=12\n",
    "    )\n",
    "    text_chunks = text_splitter.split_documents(cleaned_docs)\n",
    "    return text_chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "00c1fff8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of text chunks: 501\n"
     ]
    }
   ],
   "source": [
    "text_chunks=text_split(cleaned_docs)\n",
    "print(f\"Number of text chunks: {len(text_chunks)}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "cebe00dc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Diabetic Macular Edema (DME) Comprehensive KB'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='KB Entry 1 Short Definition Diabetic Macular'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Macular Edema (DME) is a visionthreatening'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retinal condition caused by fluid'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='by fluid accumulation within the macula due'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='macula due to breakdown of the bloodretinal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='barrier in diabetic retinopathy. It leads to'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='It leads to intraretinal cysts, retinal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retinal thickening, and sometimes subretinal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='subretinal fluid, all visible on OCT. 2'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='on OCT. 2 Pathophysiology - Chronic'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Chronic hyperglycemia damages retinal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retinal capillary endothelial cells and'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='cells and pericytes. - Loss of pericytes'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='pericytes microaneurysms and capillary'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='capillary leakage. - Increased VEGF and'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='VEGF and inflammatory cytokines promote'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='promote vascular permeability. - Breakdown'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Breakdown of the inner bloodretinal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='barrier causes fluid entry into retinal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retinal layers. - Fluid accumulates as'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='as intraretinal cystoid spaces, spongiform'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='spongiform thickening, and occasionally'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='subretinal fluid. - Chronic DME results in'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='results in photoreceptor layer disruption'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='disruption and poor visual prognosis. 3 Key'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='3 Key OCT Imaging Features (LayerLevel) -'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- **Intraretinal cystoid spaces (IRF):**'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='(IRF):** Hyporeflective, round pockets'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='pockets mainly in inner nuclear layer and'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='layer and outer plexiform layer. - **Diffuse'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- **Diffuse retinal thickening:** Spongiform'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Spongiform appearance with loss of normal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='of normal retinal layer definition. -'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- **Subretinal fluid (SRF):** Hyporeflective'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='space beneath the neurosensory retina in'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retina in more severe cases. - **Hard'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- **Hard exudates:** Hyperreflective foci,'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='foci, often located in outer plexiform'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='plexiform layer. - **Ellipsoid zone and ELM'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='and ELM disruption:** Indicates'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Indicates photoreceptor injury poorer'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='poorer prognosis. - **Foveal contour'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='contour changes:** Flattening or focal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='or focal elevation depending on edema'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='on edema pattern. - **Vitreomacular traction'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='traction (VMT):** Occasionally contributes'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='contributes to persistent edema. 4'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='edema. 4 Classification / Patterns of DME'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='of DME (OCTBased) - **Diffuse retinal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retinal thickening (DRT):** Spongiform'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Spongiform swelling. - **Cystoid macular'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='macular edema (CME):** Presence of'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Presence of wellformed cysts. - **Serous'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- **Serous retinal detachment (SRD):** SRF'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='SRF without RPE detachment. - **Mixed'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- **Mixed type:** Combination of the above.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='the above. - **Tractional / VMTassociated:**'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Structural traction contributes to edema'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='to edema persistence. 5 Diagnosis Diagnosis'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Diagnosis is based on: - OCT showing'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='OCT showing intraretinal cysts, thickening,'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='thickening, or SRF. - Evidence of diabetic'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='of diabetic retinopathy on fundus'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='on fundus examination. - Symptoms: blurred'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='blurred central vision, fluctuating vision,'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='vision, difficulty reading. 6 Treatment'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='6 Treatment Overview (Detailed)'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='DME treatment is individualized based on OCT'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='on OCT findings, visual acuity, systemic'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='systemic factors, and patient-specific'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='considerations. ### A. FirstLine: AntiVEGF'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='AntiVEGF Intravitreal Injections These'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='These agents reduce vascular permeability'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='and improve edema. 1. **Aflibercept'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='(Eylea)** - Dose: 2 mg (0.05 mL)'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='(0.05 mL) intravitreal. - Protocol: Monthly'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Monthly for 5 injections then every 8 weeks'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='8 weeks or treat-and-extend. - Particularly'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='effective for patients with poor baseline'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='baseline vision. 2. **Ranibizumab'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='(Lucentis)** - Dose: 0.3 mg (US) or 0.5 mg'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='or 0.5 mg (global) intravitreal. - Protocol:'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Protocol: Monthly until stable then PRN or'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='then PRN or T&E.; - Well-studied in DME with'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='in DME with robust visual gains. 3.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='gains. 3. **Bevacizumab (Avastin)**'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='(Avastin)** (Off-label but widely used) -'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='used) - Dose: 1.25 mg intravitreal. -'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Cost-effective option; commonly used in'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='used in resource-limited settings. ### B.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='### B. Steroid Therapy (for chronic or'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='chronic or antiVEGF nonresponders) Useful'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Useful for inflammatory components of DME.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='of DME. 1. **Dexamethasone intravitreal'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='implant (Ozurdex)** - Provides sustained'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='sustained release. - Effective for ~34'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='for ~34 months; repeat dosing needed. 2.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='needed. 2. **Fluocinolone acetonide implant'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='implant (Iluvien)** - Long-acting (up to 36'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='(up to 36 months). - For chronic, recurrent'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='recurrent DME insufficiently responsive to'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='to other treatments. **Side effects of'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='effects of steroids:** IOP rise, cataract'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='cataract progression monitor closely. ### C.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='### C. Focal / Grid Laser Photocoagulation -'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Historically first-line; now adjunctive. -'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Used in noncenter involving DME or when'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='DME or when microaneurysms are focal sources'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='sources of leakage. - Helps stabilize edema'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='edema rather than improve vision'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='vision significantly. ### D. Surgical'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='D. Surgical Approaches - **Vitrectomy**'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='indicated for tractional DME or significant'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='significant VMT. 7 Systemic Management'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Management (Important for Chatbot) DME'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='DME outcomes heavily depend on systemic'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='on systemic control:'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Tight blood glucose control (HbA1c'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='(HbA1c optimization). - Control blood'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='blood pressure and lipids. - Renal disease'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='disease management. - Lifestyle'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Lifestyle modifications (diet, exercise,'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='exercise, smoking cessation). 8 Patient'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='8 Patient Precautions & Advice - Regular'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Regular follow-up visits with OCT imaging'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='OCT imaging are essential. - Report sudden'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='sudden vision loss or new floaters'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='floaters immediately. - Do not skip diabetes'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='diabetes medications; coordinate with'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='with primary care. - Understand that'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='that treatment often requires repeated'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='repeated injections; long-term therapy is'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='therapy is common. 9 Injection Procedure'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Procedure Precautions (Safety) - Topical'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Topical povidone-iodine is essential'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='essential antisepsis. - Sterile technique:'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='technique: gloves, mask, eyelid retraction.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retraction. - Avoid routine topical'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='topical antibiotics before/after injection.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='injection. - Warn patients about'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='about endophthalmitis symptoms (pain, vision'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='vision loss, redness). - Mild irritation or'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='or foreign-body sensation is normal for 24'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='for 24 hours. 10 Prognosis - AntiVEGF'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- AntiVEGF therapy improves or stabilizes'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='stabilizes vision in many patients. - Poor'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Poor prognostic markers include: - Chronic'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Chronic edema - Photoreceptor layer'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='layer disruption - Presence of large cysts'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='large cysts or SRF - Severe ischemia on'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='ischemia on angiography - Early detection'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='detection and consistent treatment improve'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='improve outcomes. 11 Decision Flow (For'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Flow (For Chatbot Response Logic) - OCT'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- OCT shows IRF/SRF with diabetic history'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='history suggest active DME needs retina'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retina specialist and antiVEGF therapy. - No'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- No center involvement and mild leakage may'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='leakage may be observed or treated with'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='with focal laser. - AntiVEGF non-responder'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='consider steroids or evaluate for tractional'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='tractional components. - If VMT present'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='VMT present surgical opinion needed. 12 KB'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='12 KB Snippets (Ready for Embedding) - DME'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- DME is swelling in the central retina'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='retina caused by diabetes-related leakage.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='leakage. It creates intraretinal cysts'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='cysts visible on OCT. - Most cases require'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='require antiVEGF injections; some chronic'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='chronic cases respond better to steroid'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='to steroid implants. - Tight blood sugar and'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='sugar and blood pressure control greatly'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='greatly improve DME outcomes.'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='- Report sudden vision loss immediatelymay'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='indicate worsening edema or hemorrhage. 13'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='13 Disclaimer This information is'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='is educational only and not a substitute for'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='for personalized medical advice. Treatment'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='Treatment plans vary; consult a retina'),\n",
       " Document(metadata={'source': 'Data/DME_KB_Document.pdf'}, page_content='a retina specialist for individualized care.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Normal Retina Comprehensive KB Entry 1 Short'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='1 Short Definition A normal retina is a'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='retina is a multilayered neural tissue'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='tissue lining the back of the eye,'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='of the eye, responsible for converting light'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='light into visual signals. On OCT imaging,'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='imaging, the normal macula shows a clean'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='a clean foveal depression, well-defined'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='retinal layers, and absence of any fluid,'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='any fluid, cysts, or abnormal elevations. 2'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='2 Basic Anatomy of the Retina (Layer by'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(Layer by Layer) From inner (vitreous side)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='side) to outer (RPE/choroid side), the key'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='the key layers are: - Internal Limiting'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Limiting Membrane (ILM) - Nerve Fiber Layer'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Fiber Layer (NFL) - Ganglion Cell Layer'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Cell Layer (GCL) - Inner Plexiform Layer'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Layer (IPL) - Inner Nuclear Layer (INL) -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(INL) - Outer Plexiform Layer (OPL) - Outer'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Outer Nuclear Layer (ONL) - External'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- External Limiting Membrane (ELM) -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(ELM) - Photoreceptor Inner Segments and'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='and Outer Segments - Ellipsoid Zone (EZ) -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Zone (EZ) - Retinal Pigment Epithelium (RPE)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(RPE) - Bruchs Membrane and Choroid beneath'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='beneath 3 OCT Characteristics of a Healthy'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='a Healthy Macula - **Foveal Depression:**'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Smooth, symmetric curvature with thinnest'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='thinnest point at the fovea. - **Layer'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- **Layer Clarity:** All retinal layers'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='layers appear sharply demarcated. - **No'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- **No Fluid:** No intraretinal cysts (IRF)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='cysts (IRF) and no subretinal fluid (SRF). -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='(SRF). - **Intact Ellipsoid Zone:** Strong'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Strong hyperreflective band indicating'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='indicating healthy photoreceptors. -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- **Normal RPE Line:** Continuous, smooth'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='smooth hyperreflective line with no'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='with no elevation. - **Stable Thickness:**'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Normal macular thickness without thickening'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='thickening or thinning. 4 What Is NOT'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='What Is NOT Present in a Normal Retina'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Retina (Important for Classification) - No'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- No cystoid spaces. - No drusen or sub-RPE'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='or sub-RPE deposits. - No pigment epithelial'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='epithelial detachment (PED). - No choroidal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='choroidal neovascularization or subretinal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='subretinal hyperreflective material. - No'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- No edema, exudates, or hemorrhage. - No'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- No tractional changes or disruption of the'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='of the photoreceptor bands. 5 Physiological'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Variations (Still Considered Normal)'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Mild inter-individual variation in foveal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='in foveal pit shape. - Slight differences in'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='in reflectivity due to age. - Occasional'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Occasional benign vitreomacular adhesion'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='adhesion (VMA) without traction. 6'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='traction. 6 Importance in Machine Learning /'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Learning / Classification A normal OCT class'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='OCT class acts as: - The baseline template'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='template for retinal architecture. - The'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- The reference to detect abnormalities such'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='such as fluid, drusen, or neovascular'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='neovascular membranes. - A stabilizing'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='stabilizing anchor in the model for contrast'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='contrast between pathological and healthy'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='and healthy states. 7 Clinical Significance'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='of Normal Findings - Normal OCT suggests no'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='suggests no active retinal disease. - Clear'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Clear layers and intact EZ correspond to'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='to good visual potential. - Important for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='for ruling out diabetic macular edema,'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='edema, drusen, and CNV. 8 Patient Education'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Education (Chatbot-Friendly Snippets) - A'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- A normal retina has smooth, well-organized'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='layers with no swelling or abnormal fluid. -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='fluid. - Your OCT scan shows no signs of'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='no signs of leakage, deposits, or damage. -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='damage. - An intact photoreceptor layer'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='layer means healthy visual function. 9 When'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='9 When Normal OCT Occurs Despite Symptoms A'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Symptoms A patient may feel symptoms but'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='but still have a normal OCT due to: - Dry'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='to: - Dry eye symptoms (not retinal). -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='retinal). - Migraine aura. - Functional'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Functional visual disturbances. - Early'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- Early disease not yet visible'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='yet visible structurally. 10 Safety & Advice'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='& Advice for Patients with Normal OCT - If'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='OCT - If vision symptoms persist, a clinical'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='a clinical exam may still be needed. -'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='needed. - Monitor for any new distortion or'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='or vision changes. - Maintain regular eye'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='regular eye health practices (good lighting,'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='lighting, glucose control if diabetic,'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='diabetic, etc.). 11 Decision Flow (for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='Flow (for Chatbot Use) - OCT shows no fluid'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='no fluid + intact layers classify as NORMAL.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='as NORMAL. - If symptoms but OCT normal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='OCT normal recommend clinical evaluation for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='for non-retinal causes. - If minimal benign'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='benign variations still NORMAL unless'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='unless accompanied by structural'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='structural abnormalities. 12 Snippets for'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='for Embedding - Normal OCT: clear layers, no'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='layers, no fluid, intact RPE and'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='RPE and photoreceptors. - Healthy macula'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='macula shows a smooth foveal dip with no'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='dip with no cysts or swelling.'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='- No signs of drusen, edema, or abnormal'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='or abnormal vessels. 13 Disclaimer This'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='This information is for educational use only'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='use only and should not replace clinical'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='clinical assessment by an eye care'),\n",
       " Document(metadata={'source': 'Data/NORMAL_KB_Document.pdf'}, page_content='an eye care professional.'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Choroidal Neovascularization (CNV)'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(CNV) Comprehensive KB Entry 1 Short'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='1 Short definition Choroidal'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Choroidal neovascularization (CNV) is a'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(CNV) is a process in which abnormal blood'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='blood vessels grow from the choroid through'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='through breaks in Bruchs membrane into'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='into sub-RPE and/or subretinal spaces,'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='spaces, causing fluid leakage, haemorrhage,'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='and disruption of normal retinal'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='retinal architecture visible on OCT. 2'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='on OCT. 2 Pathophysiology New vessels'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='New vessels originate from the choroid and'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='choroid and invade across Bruchs membrane.'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='membrane. Leakage from these vessels'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='vessels produces subretinal fluid (SRF),'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(SRF), intraretinal fluid (IRF), and'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(IRF), and subretinal hemorrhage; chronic'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='chronic leakage causes scarring and'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='and photoreceptor loss. 3 Imaging modalities'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='modalities Spectral-domain OCT (SD-OCT) /'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(SD-OCT) / Swept-source OCT primary imaging'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='imaging for structural changes (fluid, PEDs,'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='PEDs, SHRM). OCT Angiography (OCTA)'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(OCTA) visualizes CNV networks and detects'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='and detects flow within lesions. Fluorescein'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Fluorescein angiography (FA) useful when OCT'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='when OCT or OCTA are inconclusive. 4 OCT'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='4 OCT appearances layer-level description'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='description Subretinal Hyperreflective'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Material (SHRM): hyperreflective'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='dome/elevation above RPE; often contains'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='contains neovascular tissue. Pigment'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Pigment Epithelial Detachment (PED):'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(PED): elevation of RPE from Bruchs'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='from Bruchs membrane; often irregular in'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='in CNV. Subretinal Fluid (SRF):'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(SRF): hyporeflective space between retina'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='retina and RPE. Intraretinal Fluid (IRF):'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(IRF): cystoid hyporeflective pockets inside'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='inside the retina. 5 Diagnostic criteria'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='criteria Symptoms + OCT structural evidence'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='evidence (SRF/IRF/SHRM/PED) + confirmation'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='of neovascular flow on OCTA or leakage on FA'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='on FA when needed. 6 Staging / activity'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='/ activity Active CNV: presence of new or'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='of new or worsening SRF or IRF. Inactive'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Inactive CNV: absence of fluid, presence of'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='presence of stable scar tissue. 7 First-line'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='First-line treatment Anti-VEGF agents'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='agents Ranibizumab: 0.5 mg intravitreal'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='monthly or treat-and-extend. Aflibercept: 2'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='2 mg; loading phase monthly 3 then every 8'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='every 8 weeks or T&E.; Bevacizumab: 1.25 mg'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='1.25 mg intravitreal (off-label).'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='8 Other therapies Photodynamic therapy (PDT)'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(PDT) for select cases (less common today).'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='today). 9 Procedural precautions Use'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Use povidone-iodine antisepsis, sterile'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='sterile technique, avoid routine'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='routine antibiotics, counsel patient on'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='patient on warning signs of endophthalmitis.'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='10 Complications Endophthalmitis,'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='inflammation, retinal detachment (rare), IOP'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='(rare), IOP spikes. 11 Patient precautions'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='precautions Report sudden vision worsening'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='worsening immediately. Maintain follow-ups.'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='follow-ups. Control systemic vascular risks.'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='risks. Expect mild discomfort'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='discomfort post-injection. 12 Prognosis'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Prognosis Timely anti-VEGF treatment'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='treatment stabilizes or improves vision in'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='vision in many cases; prognosis depends on'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='depends on chronicity and photoreceptor'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='layer integrity. 13 Decision flow (for'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='flow (for chatbot logic) If OCT shows active'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='active fluid urgent retina care + anti-VEGF'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='+ anti-VEGF standard. If OCT shows no fluid'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='no fluid observe or extend treatment'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='treatment interval. 14 Disclaimer'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='Disclaimer Educational information only; not'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='only; not a substitute for professional'),\n",
       " Document(metadata={'source': 'Data/CNV_KB_Document.pdf'}, page_content='medical advice.'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='Drusen Comprehensive KB Entry 1 Short'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='1 Short definition Drusen are extracellular'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='lipid-rich deposits that accumulate between'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='between the retinal pigment epithelium (RPE)'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content=\"(RPE) and Bruch's membrane. They are a\"),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='They are a hallmark sign of age-related'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='age-related macular degeneration (AMD)'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='(AMD) spectrum but as an OCT feature they'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='they appear as RPE elevations with variable'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='variable reflectivity. 2 Pathophysiology'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='Drusen form from metabolic byproducts of the'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='of the outer retina and RPE. Small hard'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='Small hard drusen may be benign, whereas'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='whereas large soft or confluent drusen'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='drusen increase risk of progression to'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='to advanced disease (geographic atrophy or'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='atrophy or choroidal neovascularization). 3'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='3 Imaging modalities Spectral-domain OCT'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='OCT (SD-OCT) / Swept-source OCT primary tool'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='tool to visualize drusen morphology (RPE'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='(RPE elevations, hyperreflective foci).'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='foci). Color fundus photography shows'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='shows yellowish deposits. Autofluorescence'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='imaging useful to assess overlying RPE'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='RPE health. 4 OCT appearances layer-level'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='layer-level description - RPE Elevation:'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='Elevation: focal dome-like elevation of the'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='of the RPE overlying'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='overlying hyporeflective/heterogeneous'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='material. - Drusen types: hard drusen'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='hard drusen (small, discrete), soft drusen'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='soft drusen (larger, confluent), cuticular'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='cuticular drusen (numerous, small). -'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='small). - Hyperreflective foci: small'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='foci: small reflective dots above drusen'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='drusen suggesting migration of RPE cells or'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='cells or inflammatory cells. - Overlying'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='- Overlying photoreceptor/ellipsoid zone'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='zone integrity: disruption suggests higher'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='higher risk of vision loss. 5 Grading /'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='5 Grading / staging (imaging-based) -'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='- **Normal / No drusen**: no sub-RPE'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='no sub-RPE deposits. - **Early**: few small'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='few small drusen; minimal risk. -'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='risk. - **Intermediate**: medium/large'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='drusen or pigmentary changes; increased risk'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='risk of progression. - **Advanced**:'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='development of geographic atrophy or CNV'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='or CNV (refer for treatment). 6 Clinical'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='6 Clinical significance - Large/soft drusen'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='drusen and pigmentary changes correlate with'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='with higher risk of progression to advanced'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='to advanced disease. - Drusen themselves may'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='may be asymptomatic but serve as an'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='serve as an important biomarker on OCT. 7'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='on OCT. 7 Management & interventions -'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='- **Observation and monitoring**: regular'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='regular OCT and fundus exams depending on'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='on drusen size and risk. - **Lifestyle'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='**Lifestyle interventions**: smoking'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='smoking cessation, healthy diet, control of'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='control of cardiovascular risk factors. -'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='factors. - **AREDS2 supplementation**:'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='evidence supports specific vitamin/mineral'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='formulations for patients with intermediate'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='AMD to slow progression (not useful for'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='useful for early/no drusen). - **No routine'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='routine invasive treatment for drusen'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='for drusen alone**; treat complications'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='(CNV) if they occur.'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='8 Patient precautions & advice - Encourage'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='- Encourage regular follow-ups with OCT'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='with OCT imaging. - Self-monitoring using an'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='using an Amsler grid and reporting new'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='new distortion or central vision loss'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='vision loss promptly. - Avoid smoking;'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='smoking; maintain healthy diet and control'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='and control systemic risk factors. 9'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='factors. 9 Prognosis - Many patients with'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='with small drusen remain stable for years. -'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='years. - Presence of large/confluent drusen'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='drusen and pigmentary changes increases risk'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='risk of progression; timely monitoring and'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='and AREDS2 for eligible patients can reduce'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='can reduce progression risk. 10 Decision'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='10 Decision flow (for chatbot logic) - If'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='logic) - If OCT shows only small isolated'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='isolated drusen and no symptoms reassure +'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='reassure + monitor. - If OCT shows'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='OCT shows large/soft drusen or pigmentary'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='pigmentary changes consider AREDS2'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='AREDS2 discussion and closer follow-up. - If'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='- If new fluid, hemorrhage, or signs of CNV'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='of CNV appear urgent retina referral. 11 KB'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='11 KB snippet suggestions (ready for'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='(ready for embedding) - Definition'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='Definition (patient): \"Drusen are small'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='are small yellow deposits under the retina.'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='the retina. They can be harmless but'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='but sometimes signal increased risk for'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='risk for macular disease.\" - Definition'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='Definition (clinician): \"Drusen are sub-RPE'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='are sub-RPE extracellular deposits; soft'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='soft drusen and pigment changes indicate'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='indicate higher progression risk.\" -'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='risk.\" - Management summary: \"Monitor with'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='with OCT; lifestyle changes; AREDS2 for'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='AREDS2 for intermediate disease; treat'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='treat complications if they arise.\" 12'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='arise.\" 12 Citations & sources (suggested to'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='to fetch original PDFs) - Review articles'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='articles and OCT-focused papers on drusen'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='on drusen morphology, AREDS2 trial'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='trial summaries, and imaging guides (search'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='(search in PubMed Central / ophthalmology'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='journals for drusen OCT morphology and'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='and AREDS2 supplementation). 13 Disclaimer'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='Disclaimer Educational information only; not'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='only; not a substitute for personalized'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='medical advice. For decisions about'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='about supplements or treatment, consult a'),\n",
       " Document(metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='consult a qualified eye care specialist.')]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text_chunks"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "397eaa43",
   "metadata": {},
   "source": [
    "Embeddings\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "f2922a93",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_13303/2696662282.py:7: LangChainDeprecationWarning: The class `HuggingFaceEmbeddings` was deprecated in LangChain 0.2.2 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-huggingface package and should be used instead. To use it run `pip install -U :class:`~langchain-huggingface` and import as `from :class:`~langchain_huggingface import HuggingFaceEmbeddings``.\n",
      "  embeddings = HuggingFaceEmbeddings(\n"
     ]
    }
   ],
   "source": [
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "def text_embedding():\n",
    "    \"\"\"\n",
    "    Download and Return HuggingFace Embeddings model.\n",
    "    \"\"\"\n",
    "    Model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "    embeddings = HuggingFaceEmbeddings(\n",
    "        model_name=Model_name\n",
    "\n",
    "        )\n",
    "    return embeddings\n",
    "\n",
    "embeddings = text_embedding()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "89be5990",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "load_dotenv()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "62d7c775",
   "metadata": {},
   "outputs": [],
   "source": [
    "PINECONE_API_KEY = os.getenv(\"PINECONE_API_KEY\")\n",
    "GOOGLE_API_KEY = os.getenv(\"GOOGLE_API_KEY\")\n",
    "\n",
    "os.environ[\"PINECONE_API_KEY\"] = PINECONE_API_KEY\n",
    "os.environ[\"GOOGLE_API_KEY\"] = GOOGLE_API_KEY"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "71726a59",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<pinecone.pinecone.Pinecone at 0x79b6b0246e70>"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from pinecone import Pinecone\n",
    "pinecone_api_key = PINECONE_API_KEY\n",
    "pc = Pinecone(api_key=pinecone_api_key) #for connecting to pinecone database, pc is picone connect\n",
    "\n",
    "pc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "a8099cb3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[\n",
       "    {\n",
       "        \"name\": \"eye-disease-chatbot\",\n",
       "        \"metric\": \"cosine\",\n",
       "        \"host\": \"eye-disease-chatbot-kuovyk1.svc.aped-4627-b74a.pinecone.io\",\n",
       "        \"spec\": {\n",
       "            \"serverless\": {\n",
       "                \"cloud\": \"aws\",\n",
       "                \"region\": \"us-east-1\"\n",
       "            }\n",
       "        },\n",
       "        \"status\": {\n",
       "            \"ready\": true,\n",
       "            \"state\": \"Ready\"\n",
       "        },\n",
       "        \"vector_type\": \"dense\",\n",
       "        \"dimension\": 384,\n",
       "        \"deletion_protection\": \"disabled\",\n",
       "        \"tags\": null\n",
       "    }\n",
       "]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pc.list_indexes()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "e6e06fb9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# from pinecone import ServerlessSpec\n",
    "# index_name = \"eye-disease-chatbot\"\n",
    "# if not pc.has_index(index_name):\n",
    "#     pc.create_index(\n",
    "#         name=index_name,\n",
    "#         dimension=384, #Dimenstion of embedings , if you know Dimension you can directly pass it\n",
    "#         metric=\"cosine\", #for similarity search\n",
    "#         spec=ServerlessSpec(\n",
    "#             cloud = \"aws\",\n",
    "#             region = \"us-east-1\"\n",
    "#         )\n",
    "#     )\n",
    "\n",
    "# index = pc.Index(index_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "41d3ed0d",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_pinecone import PineconeVectorStore\n",
    "docsearch = PineconeVectorStore.from_documents(\n",
    "    documents = text_chunks,\n",
    "    embedding=embeddings,\n",
    "    index_name=\"eye-disease-chatbot\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "e739870c",
   "metadata": {},
   "outputs": [],
   "source": [
    "restriver = docsearch.as_retriever(search_type=\"similarity\", search_kwargs={\"k\":3})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "7b9e607e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id='e6ac7d3c-8125-4d9f-b3cb-e437fa99d3f6', metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='articles and OCT-focused papers on drusen'),\n",
       " Document(id='8953fc52-e780-4112-8a38-b80bd50ab46b', metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='routine invasive treatment for drusen'),\n",
       " Document(id='fb2c9dcd-78fd-436f-8145-977821c9a29f', metadata={'source': 'Data/DRUSEN_KB_Document.pdf'}, page_content='Definition (clinician): \"Drusen are sub-RPE')]"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "restriver.invoke(\"what is Drusen?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "3b723f5a",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_google_genai import ChatGoogleGenerativeAI\n",
    "ChatModel = ChatGoogleGenerativeAI(model=\"gemini-2.5-flash\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "3bafac23",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import create_retrieval_chain\n",
    "from langchain.chains.combine_documents import create_stuff_documents_chain\n",
    "from langchain_core.prompts import ChatPromptTemplate"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "f666b304",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = (\n",
    "    \"You are a helpful medical assistant specializing in eye diseases. \"\n",
    "    \"Answer questions based on the provided context from reliable medical sources. \"\n",
    "    \"If the context doesn't fully cover the query, use your general knowledge to provide accurate, concise information. \"\n",
    "    \"Be clear, concise, and empathetic. Always advise consulting a qualified eye care professional for diagnosis or treatment. if they ask for medical advaice. \"\n",
    "    \"By the given context answer the questions carefully without menstioning that you are an AI language model. \"\n",
    "    \"when they ask you about the any disease provide the all the information that you in the context and also include the general infromation form realbel medical sources. to extend the answer in clear way.\"\n",
    "    \"Do not provide medical advice or diagnoses. \"\n",
    "    \"\\n\\n\"\n",
    "    \"{context}\"\n",
    ")\n",
    "\n",
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", system_prompt),\n",
    "    (\"user\", \"{input}\")\n",
    "])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "e6c882dc",
   "metadata": {},
   "outputs": [],
   "source": [
    "question_answer_chain = create_stuff_documents_chain(\n",
    "    llm=ChatModel,\n",
    "    prompt=prompt \n",
    ")\n",
    "rag_chain = create_retrieval_chain(restriver, question_answer_chain)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "74356d3f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CNV stands for Choroidal Neovascularization.\n",
      "\n",
      "Based on the provided context, CNV is described as a process in which abnormal blood vessels grow. These abnormal blood vessels originate from the choroid, which is the layer of blood vessels supplying blood to the retina, and extend into or under the retina.\n",
      "\n",
      "These newly formed blood vessels are often fragile and can leak fluid or blood, which can significantly disrupt the normal function of the retina and lead to vision loss. CNV is a common and serious complication of various eye conditions, most notably age-related macular degeneration (AMD), but can also occur with other conditions like high myopia, inflammatory eye diseases, or trauma.\n",
      "\n",
      "The context also mentions that CNV can be active or inactive. **Inactive CNV** refers to a state where there is an absence of fluid, though the presence of the abnormal vessels remains. Active CNV, conversely, would involve signs of leakage or bleeding.\n",
      "\n",
      "If you have concerns about CNV or your eye health, it is essential to consult a qualified eye care professional for an accurate diagnosis and appropriate management.\n"
     ]
    }
   ],
   "source": [
    "response = rag_chain.invoke({'input': \"What is cnv?\"})\n",
    "print(response[\"answer\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b4c52320",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "I don't have information on what DME stands for or what it is. Please consult a qualified eye care professional for diagnosis or treatment.\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "59f87f64",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "medchatenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
